| Document |
Document Title |
|
WO/2022/146725A1 |
Large-area medical graft devices comprise at least two sheets of extracellular matrix material (ECM). The sheets of ECM have overlapping regions that are compressed together during a non-drying process, and other overlapping regions that...
|
|
WO/2022/133626A1 |
A rapid film-forming liquid band-aid, comprising the following components in parts by weight: 10-15 parts of a polyacrylic resin, 10-25 parts of polyvinyl butyral, 7-15 parts of polyvinyl alcohol, 15-30 parts of carboxymethyl chitosan, 1...
|
|
WO/2022/136666A1 |
The present invention provides a method for obtaining in situ self-assembled nanocomposite hydrogel with multiple functionalities which comprises nanoparticles (NPs) with phenolic-shell and biopolymers bearing nucleophilic groups. This i...
|
|
WO/2022/133628A1 |
A degradable liquid Band-Aid, comprising the following components in parts by weight: 30-40 parts of keratin, 15-30 parts of methyl cellulose, 10-25 parts of carboxymethyl chitosan, 2-6 parts of polyvinylpyrrolidone-vinyl acetate copolym...
|
|
WO/2022/133629A1 |
A spray type liquid bandage, comprising the following components in parts by weight: 20-30 parts of ethyl cellulose, 6-10 parts of carboxymethyl chitosan, 3-5 parts of a polyvinylpyrrolidone-vinyl acetate copolymer, 15-25 parts of ethano...
|
|
WO/2022/138993A1 |
The present invention relates to a composition for treating a wound comprising a dermis-derived extracellular matrix and a method for preparing same. By using the composition for treating a wound according to the present invention, the c...
|
|
WO/2022/132136A1 |
A novel hydrogel wound dressing therapy and methods for making the same. The novel methods comprise forming two biopolymers, chitosan and hyaluronic acid, together into a wound dressing with inherent ability to enhance wound closure. The...
|
|
WO/2022/126628A1 |
A liquid adhesive bandage, comprising the following components in percentage by weight: 10-20 parts of a main film-forming agent, i.e., ethyl cellulose, 6-15 parts of an auxiliary film-forming agent, i.e., carboxymethyl chitosan, 3-5 par...
|
|
WO/2022/126629A1 |
A liquid adhesive bandage, comprising the following component in percentage by weight: 15-25 parts of ethyl cellulose, 10-20 parts of carboxymethyl chitosan, 5-15 parts of hydroxyethyl cellulose, 5-10 parts of hydroxypropyl methyl cellul...
|
|
WO/2022/117842A1 |
The invention relates to a plaster composition comprising at least one resorbable polymer made of at least three monomer units, in particular a terpolymer, comprising monomers selected from the group consisting of trimethylene carbonate,...
|
|
WO/2022/117499A1 |
The present invention relates to formulations in the form of a cream, an ointment, a liquid, or a gel and to the use of same to accelerate the healing of wounds and ulcers of mucous membranes and skin. The components of these formulation...
|
|
WO/2022/117844A1 |
The invention relates to a two-dimensional material for the medical wound area treatment, comprising a non-woven fabric (12) consisting of resorbable polymer filaments (14), and collagen particles (16) which have a particle size I > 80 Â...
|
|
WO/2022/112364A2 |
In various embodiments a biocompatible composite membrane for in vitro cell culturing comprising a first material, which is non-water soluble and a water soluble second material is provided, wherein the composite membrane comprises a por...
|
|
WO/2022/100519A1 |
Disclosed are a hyaluronic acid composition having permeation-promoting effects, a preparation method therefor and the use thereof. Provided is a hyaluronic acid composition, comprising: hyaluronic acid or a salt thereof, an acetylated h...
|
|
WO/2022/089295A1 |
The present invention relates to the field of biological materials, particularly to a bionic collagen aqueous solution, and a preparation method therefor and a use method thereof. According to the invention, by adding simulated body flui...
|
|
WO/2022/084987A1 |
The present invention provides pharmaceutical formulations in the form of a hydrogel which comprise a proteolytic enzyme mixture obtained from bromelain and a water-soluble gelling agent, for use in treating non-melanoma skin cancers, pr...
|
|
WO/2022/087519A1 |
Surface modified scaffolds are provided as well as methods of use thereof and methods of making.
|
|
WO/2022/084478A1 |
Methods and products for surgery, in particular products and methods for preventing surgical adhesion, for stopping or reducing bleeding in an open surgical wound, and for treating surgical wounds. preventing surgical adhesion between su...
|
|
WO/2022/053220A1 |
The present invention relates to a wound closure preparation containing an active substance, in particular to a sprayable wound closure preparation containing an active substance.
|
|
WO/2022/053485A1 |
The invention relates to a pharmaceutical composition in a hydrogel form, comprising orange-derived extracellular vesicles (EVs) having a diameter ranging from 10 to 500 nm and showing pro-angiogenic activity, for use in a tissue repair ...
|
|
WO/2022/053222A1 |
The invention relates to a wound closure preparation containing an active substance, in particular to a sprayable wound closure preparation containing an active substance.
|
|
WO/2022/050859A1 |
An object of the invention is a membrane-forming pharmaceutical composition and its use min for the prevention of bacterial infections or infections in humans and animals.
|
|
WO/2022/035778A1 |
Methods of administering biological material to a subject are provided. Methods of culturing biological material are also provided. The methods include combining biological material with a thermally stable preparation having a purified a...
|
|
WO/2022/030540A1 |
The present invention pertains to a film-forming skin composition that comprises (a1) an ethyl acrylate-methyl methacrylate-trimethylammonium chloride ethyl methacrylate copolymer and (a2) an ethyl acrylate-methyl methacrylate copolymer....
|
|
WO/2022/029938A1 |
The present invention relates to a membrane forming skin composition that contains (a1) an ethyl acrylate-methyl methacrylate-trimethyl ammonium ethyl chloride methacrylate copolymer, and (a2) an ethyl acrylate-methyl methacrylate copoly...
|
|
WO/2022/019467A1 |
The present invention relates to a topical hemostatic powder composition and a preparation method therefor and, more specifically, to a technology of providing a powder-type hemostatic agent which comprises a super absorbent polymer and ...
|
|
WO/2022/018689A1 |
The invention relates to mesh materials for the controlled release of antimicrobial and antiviral compounds, with high antiviral activity and efficacy, predominantly against coronavirus, and to a method for producing mesh materials with ...
|
|
WO/2021/256751A1 |
The present invention relates to a composition comprising fibroblast-derived extracellular vesicles as an active ingredient for treating skin and mucosal wounds. It is identified that the fibroblast-derived extracellular vesicles are eff...
|
|
WO/2021/248197A1 |
The present invention provides a composition for controlling bleeding, said composition comprising a non-acidic meshed network of fibrous material, wherein the network comprises fibres with a mean diameter (D50) no greater than 1µm, an ...
|
|
WO/2021/252305A1 |
The disclosure concerns various devices implemented to provide a therapeutic gas rich environment to promote healing, reduce fibrosis and scar formations while maintaining anti-inflammatory, anti-thrombotic, antimicrobial, and vasodilati...
|
|
WO/2021/240357A1 |
Novel compositions and systems for closure of wounds with antimicrobial effectiveness are disclosed. The compositions provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure dev...
|
|
WO/2021/240355A1 |
Novel compositions and systems for closure of wounds are disclosed. The compositions provide devices of improved flexibility and elasticity and are readily applied to wound sites or over wound closure devices. The present invention is al...
|
|
WO/2021/240363A1 |
An aerosol spray device includes a container having first and second fluid reservoirs disposed therein that are divided from one another. The first fluid reservoir holds a first mixture including a first aerosol propellant and a first pa...
|
|
WO/2021/236231A1 |
Provided herein are formulations containing copper ions and methods of treating underlying infections and conditions caused by coronavirus, particularly COVID-19, and influenzas, particularly influenza A and/or influenza B using such for...
|
|
WO/2021/228292A1 |
The kit of at least two aqueous gel-forming solutions for the preparation of a biodegradable hydrogel based on a covalently crosslinked hydroxyphenyl derivative of hyaluronan, comprising at least two aqueous solutions A and B, of which t...
|
|
WO/2021/229538A1 |
A method for obtaining a bioactive hemostatic agent according to the invention, wherein the chitosan is subjected to a physical cross-linking reaction with poly(aspartic acid), and then the lysozyme is incorporated into the structure of ...
|
|
WO/2021/224919A1 |
Compositions comprised of oxidized cellulose (OC) in the form of a powder, wherein the carboxyl content of the OC is about 9% to about 18%, by weight, are disclosed. Optionally, the powder is in an aggregated form. Uses of the compositio...
|
|
WO/2021/223756A1 |
Disclosed are a hydrogel having an anti-inflammatory and repair-promoting function, a preparation method therefor and an application thereof. The injectable hydrogel forms a gel by means of interaction between a functional group of a pol...
|
|
WO/2021/212017A1 |
Compositions including a plurality of particles that may be prepared from a chitosan salt and methods for preparing the same. The plurality of particles may have an average diameter ranging from about 100 μm to about 750 μm, such as fr...
|
|
WO/2021/204843A1 |
The present invention relates to a topical composition comprising erlotinib and a pharmaceutically acceptable excipient for use in the treatment of a keratoderma in a child, preferably a palmoplantar keratoderma (PPK), wherein the compos...
|
|
WO/2021/205167A1 |
The present invention relates to the use of jellyfish collagen in the treatment of wounds and the manufacture of said jellyfish collagen.
|
|
WO/2021/205457A1 |
Provided by this disclosure is a method and system for the preparation of a blood clot-based wound dressing whereby a fluid, typically gas such as air is propelled through one conduit into a sealed, blood-containing test tube, and at the...
|
|
WO/2021/198461A1 |
Disclosed embodiments relate to a wound dressing which can generate nitric oxide. The wound dressing may include a cover layer, an activator layer such as an acid providing layer and nitric oxide source layer, such as a nitrite providing...
|
|
WO/2021/191811A1 |
The present invention provides several wound gel compositions for accelerating wound healing and to limit scarring. The present invention also relates to wound gel compositions that can be used as a growth medium for new skin for use in ...
|
|
WO/2021/185997A1 |
The present invention relates to a new multifunctional debridement and/or antifouling composition comprising H2O2 at a final concentration of between 0.1 - 5%v/v, and a composite hydrogel formulation comprising pluronic acid at a concent...
|
|
WO/2021/183497A1 |
In some aspects, the present disclosure pertains to hydrogel-securing structures that comprise anchoring element that is configured to anchor the structure to bodily tissue and a hydrogel-retaining element that is configured to retain a ...
|
|
WO/2021/176410A1 |
The present invention describes a hemostatic agent comprising ferric and aluminum Salts, useful for the treatment of bleeding phenomena including the treatment of superficial wounds, surgical wounds, ulcers, sores or other skin lesions. ...
|
|
WO/2021/176457A1 |
Composite materials made of a citrate, a calcium carbonate-containing material and an association moiety which is associated with the citrate and the calcium carbonate-containing material are provided. The composite materials are typical...
|
|
WO/2021/174085A1 |
Provided are methods, devices and compositions for reducing and/or inhibiting postsurgical tissue adhesion using a hydrogel film disposed onto a target tissue, thereby providing an adhesion barrier that remains over said target tissue fo...
|
|
WO/2021/165251A1 |
The invention relates to an opthalmological composition (1) comprising at least one viscoelastic polymer (2) and at least one thermoresponsive compound (3), which discontinuously changes at least one physical property from the group cons...
|
